ClinicalTrials.gg
Active, not recruitingNCT04514003COVITAUpdated Nov 17, 2026

The Corona and COVID-19 Study in Telemark and Agder

An observational study in Covid19, sponsored by Sykehuset Telemark. Active, not recruiting at 1 site in Norway. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Sykehuset Telemark · Observational

How we know

Updated Nov 17, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in COVID-19 with a site in Norway — 3 open to participants now, 7 under way, 1 of them phase 3. COVID-19 · Norway.

Planned enrollment
10th of 23
1,200 · median 860
Started
2020
with 24 others
Observational
23 of 47
1 open now
Registered
15th of 47
by date

Among the 47 studies in COVID-19 with a site in Norway, this one is the 10th largest by planned enrollment of the 23 observational ones that give a count, is one of 25 that started in 2020, is one of 23 observational ones, and was the 15th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 47 studies in COVID-19 with a site in Norway are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in COVID-19 with a site in Norway, or all of them as a file.
02

Study summary

Through SARS-CoV-2 IgG testing of PCR positive and negative cases the study will follow the COVID-19 immune response by monitoring the SARS-CoV-2 IgG antibody levels over a period of two years. Further, risk factors will be identified by the use of the test-negative design including population controls, allowing comparison of participants with positive and negative tests, and with population controls (triangulation). Special emphasis will be on high risk groups in general and on different occupational, environmental and socio-economic groups in particular. Finally, severity of illness, deaths and the use of health care during will be assessed using national register data from Telemark and Agder.

Read the detailed description

Objectives

The main objectives are:

  1. Monitor the incidence of COVID-19 and the development of the SARS-CoV-2-IgG levels of cases in Agder and Telemark over a period of two years (WP1).
  2. Identify risk factors for COVID-19 by comparison of SARS-CoV-2 antibody positive and negative cases in Telemark and Agder, and comparison of these groups separately with population controls (WP2).
  3. The incidence of neurocognitive symptoms and fatigue in COVID-19 patients (WP3).
  4. Investigation of severity, death and the use of health care for the COVID-19 patients based on data from national registers (WP4).

The main exposures are (WP1-3):

  • Infection (mild, severe) with COVID-19.
  • Occupational risk factors assessed by occupational codes (ISCO88) and job exposure matrix categorisation.
  • Environmental risk factors (road traffic outside bedroom window, travel by foot or bicycle alongside busy roads, and the use of a fireplaces in residential homes. Further, estimated measurements of air pollution may be linked to participants' home address.
  • Socioeconomic status; age, sex, comorbidity, medication use, lifestyle factors (smoking, BMI, physical activity, others), geographic region/municipality, education and income.
03

Conditions studied

  • Covid19

Browse trials for

Keywords

  • Immunity
  • Risk factors
  • Test-negative design
  • Population controls
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Inhabitants of Agder and Telemark County in Norway fulfilling the inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 - 85 years
  • Performed SARS-CoV-2 PCR test

Exclusion criteria

Exclusion Criteria:

  • Non-Norwegian speakers.
  • Deceased
  • inability to answer questionnaire due to dementia or similar conditions
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • SARS-CoV-2 PCR positive cases

    Antibody tests will be performed every 6 months for 2 years

  • SARS-CoV-2 PCR negative cases

    Antibody tests will be performed at baseline

  • Population controls

    A large sample (n= 22500) from the general population will be included to assess risk factors. No blood sample will be collected for this group and the data needed is already collected.

06

What researchers measure

Primary outcomes

  1. SARS-CoV-2 IgG antibody level

    Serum Levels of SARS-CoV-2 IgG antibody and the Development of these over a two years period

    Time frame: 2020-2023

  2. Risk factors for COVID-19

    Different risk factors (age, sex, education, comorbidity, occupational and environmental exposure will be assessed

    Time frame: 2020-2026

07

Study locations

1 site
08

References and documents

Publications

  • Sarjomaa M, Berg KK, Jaioun K, Tveten Y, Kersten H, Reiso H, Eikeland R, Thilesen C, Nordbo SA, Aaberge IS, Pearce N, Fell AKM. SARS-CoV-2-specific humoral immunity in a Norwegian cohort between 2020 and 2023. BMC Med. 2025 Jun 3;23(1):332. doi: 10.1186/s12916-025-04171-2. PubMed 40462062 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Dec 2026, 77 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 77 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2020
First posted
Aug 14, 2020
StartActual
Jul 1, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2035
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Telemark Hospital · Skien, Norway
Show 1 removed
  • Telemark Hospital · Skien, Norway
Nov 17, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40462062 ↗
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40462062 ↗
    1 site added, 1 site removed
    Show site
    • Telemark Hospital · Skien, Norway
    Show 1 removed
    • Telemark Hospital · Skien, Norway
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04514003
Lead sponsor
Sykehuset Telemark
Collaborators
Sorlandet Hospital HF, Norwegian Institute of Public Health, London School of Hygiene and Tropical Medicine, Leiden University, Aalborg University
Responsible party
Anne Kristin M. Fell (Associate Professor, senior physician, Sykehuset Telemark) — Principal investigator
First posted
Aug 14, 2020
Start date
Jul 1, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Nov 17, 2026

Study contacts

Anne Kristin M. Fell, PhD
principal investigator · Sykehuset Telemark

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion